A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation.
about
Belatacept for kidney transplant recipientsA systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipientsEffect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.Chronic allograft nephropathy score before sirolimus rescue predicts allograft function in renal transplant patients.Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II studySirolimus effects on cancer incidence after kidney transplantation: a meta-analysis.Mycophenolate mofetil and sirolimus combination in renal transplantation.Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.Considerations in sirolimus use in the early and late post-transplant periods.mTOR inhibitor-associated dermatologic and mucosal problems.Adverse events associated with mTOR inhibitors.mTOR inhibitors and renal allograft: Yin and Yang.Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis.Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis.mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study.Experience with belatacept rescue therapy in kidney transplant recipients.Mucocutaneous disorders in renal transplant recipients receiving sirolimus-based immunosuppressive therapy: a prospective, case-control study.Conversion from cyclosporin A to sirolimus retards the progression of chronic allograft nephropathy in the long term in a rat kidney transplantation model.Late conversion of tacrolimus to sirolimus in a prednisone-free immunosuppression regimen in renal transplant patients.Sirolimus inhibits lymphangiogenesis in rat renal allografts, a novel mechanism to prevent chronic kidney allograft injury.Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks.Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria.Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction.Kinetic nomograms assist individualization of drug regimens.Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy.Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF-Four-Year Results of the Postconcept Study
P2860
Q24187867-3C39D3E9-0618-4FDB-8F16-8A890C32F352Q27000107-CAAB2F8B-17C4-42CD-90EE-788DCB77DF87Q30871643-39523CEC-355D-4540-B497-5DCDCD069DBAQ34236920-92C18C46-0A4E-46ED-ADA5-8D384EDC9E24Q34639752-67BC65C7-B986-4B5D-AE82-DD43851DD434Q36051817-906EB682-3C8E-4752-8472-569F3AC5974AQ36575992-F917362F-6B5F-4560-A391-C752AD5D925DQ37064446-82846ED9-B3FC-4E5A-BE89-5E9F2CB5942EQ37517602-05FBB4BC-E36B-495D-8C2C-51AD062F6E2AQ37710669-6B55AC9C-3A2E-4907-A271-DCAF5082974DQ38068519-343AF3A9-1F23-4E6E-88F0-542373B9AC3CQ38209973-FC32C5EA-4432-4A62-827C-0B495D72CC2BQ38242068-77CA7D14-4CC9-4C1C-BB2A-1AAF3B67B532Q38668601-22501257-A0AA-4EE0-95E8-FBB599D5A3FCQ38779769-7ED370C5-8663-494B-8221-16673DA88F58Q38962103-6BF1E1B1-8F62-4DEE-8E50-23A6E985EAB5Q40134922-5133A2C4-1319-4E89-AAFF-23B59487835AQ40513558-A0C40393-9BAD-485A-A390-2A6491015810Q42249276-9C599C8E-F96B-489C-B47C-8A1108495957Q43237438-38A6BD9A-EC80-494C-9819-7B6979996A63Q43297747-CE40BA3D-BDDE-480D-8A26-051531BDD653Q45883054-9DDF2247-C3CB-4A7B-AA42-4504E02FFD17Q46856408-9B4FEAE5-50B7-4C72-8167-A61EE59C0695Q46898800-4EC78FEB-8706-4313-8FF9-F6B262E4E749Q51101954-953B67B7-174E-41FB-8B11-A9276592915FQ51497219-89F8A705-BC5D-4EB0-92B8-7CEDB0AEAACEQ51788749-66B62E69-615C-46AB-A233-F408A4B09A7BQ56908066-6DC7AE35-49CB-4C3E-AACA-4AC9DE84D9E3
P2860
A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
A randomized controlled trial ...... llowing renal transplantation.
@en
A randomized controlled trial ...... llowing renal transplantation.
@nl
type
label
A randomized controlled trial ...... llowing renal transplantation.
@en
A randomized controlled trial ...... llowing renal transplantation.
@nl
prefLabel
A randomized controlled trial ...... llowing renal transplantation.
@en
A randomized controlled trial ...... llowing renal transplantation.
@nl
P2093
P2860
P1476
A randomized controlled trial ...... ollowing renal transplantation
@en
P2093
Afzal Chaudhry
Christopher R Palmer
J Andrew Bradley
Jane C Smith
John Firth
John R Bradley
Nicholas Pritchard
Paul F Williams
P2860
P304
P356
10.1111/J.1600-6143.2005.01055.X
P407
P577
2005-10-01T00:00:00Z